Launch Bundle
Retatrutide + Tesamorelin + MOTS-c research protocol
Three mechanism-distinct axes
This bundle pairs three compounds that act through independent metabolic mechanisms, assembled for investigators studying convergent incretin / pituitary / mitochondrial biology. Retatrutide is a triple agonist engaging GLP-1, GIP, and glucagon (GCGR) receptors. Tesamorelin is a stabilized GHRH(1-44) analog producing pulsatile pituitary GH with documented visceral-adipose selectivity. MOTS-c is a 16-amino-acid mitochondrial-derived peptide reported to activate AMPK energy-sensing.
- GLP-1R / GIP-R / GCGR triple agonism (Retatrutide)
- GHRH-R → cAMP/PKA pulsatile GH (Tesamorelin)
- AMPK / mitochondrial energy sensing (MOTS-c)
Lyophilized: −20°C, desiccated. Reconstituted: 2–8°C. Each compound carries its own COA and lot record.
Independent US lab tested
- ✓ Independent US laboratory analysis (HPLC, MS) per lot
- ✓ Reported purity ≥99% across constituents
- ✓ Lot-traceable COA per vial
- ✓ Sealed glass vials, butyl stopper, crimp cap
Per-compound primary citations are listed on each constituent's product page and in the Research Library. All literature is preclinical / in vitro only.
